Cyclacel Pharmaceuticals Inc CYCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYCC is a good fit for your portfolio.
News
-
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
-
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
-
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
-
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
-
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
-
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing
-
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Trading Information
- Previous Close Price
- $1.65
- Day Range
- $1.65–1.71
- 52-Week Range
- $1.30–13.20
- Bid/Ask
- $1.67 / $1.69
- Market Cap
- $2.47 Mil
- Volume/Avg
- 26,509 / 833,399
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://cyclacel.com
Valuation
|
Metric
|
CYCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 3.55 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CYCC
|
|---|---|
Quick Ratio | 0.54 |
Current Ratio | 0.58 |
Interest Coverage | — |
Quick Ratio
CYCC
Profitability
|
Metric
|
CYCC
|
|---|---|
Return on Assets (Normalized) | −140.91% |
Return on Equity (Normalized) | −344.68% |
Return on Invested Capital (Normalized) | −343.86% |
Return on Assets
CYCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Tqbpslqf | Qxxlyj | $123.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dlysfswb | Twxwr | $113.1 Bil | |||
| Moderna Inc
MRNA
| Kzgpxgj | Ltrr | $55.7 Bil | |||
| BioNTech SE ADR
BNTX
| Wdthhcbfw | Gpln | $23.1 Bil | |||
| argenx SE ADR
ARGX
| Zvtfkdbk | Pqp | $22.4 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ytpxlqyh | Dzvqxtq | $20.2 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bdpjzthq | Vmrpnr | $16.0 Bil | |||
| United Therapeutics Corp
UTHR
| Jvtmvtjn | Qhswz | $12.8 Bil | |||
| Incyte Corp
INCY
| Jqdsvpd | Lpxbn | $12.3 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bdrkgycj | Szfrtjw | $12.3 Bil |